Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Portfolio Pulse from Lisa Levin
Several big stocks recorded losses in Friday's pre-market trading session. Sleep Number Corporation shares tumbled 28.8% after mixed Q2 results. Enphase Energy shares dipped 13.7% after downbeat Q2 sales and weak sales guidance. Sweetgreen shares declined 11% after worse-than-expected Q2 results. UroGen Pharma shares fell 8.7% despite positive topline data from its Phase 3 trials. SolarEdge Technologies shares declined 5.3% after a supplier agreement with Infineon. Sanofi shares fell 3.1% after Q2 results and raised earnings forecast. Ford shares slipped 1.8% despite upbeat Q2 earnings and raised FY23 EBIT guidance.
July 28, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enphase Energy shares dipped 13.7% after downbeat Q2 sales and weak sales guidance.
The company's weak Q2 sales and sales guidance have negatively impacted its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Ford shares slipped 1.8% despite upbeat Q2 earnings and raised FY23 EBIT guidance.
Despite upbeat Q2 earnings and raised FY23 EBIT guidance, the company's stock price has slipped.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
SolarEdge Technologies shares declined 5.3% after a supplier agreement with Infineon.
Despite a supplier agreement with Infineon, the company's stock price has declined.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Sweetgreen shares declined 11% after worse-than-expected Q2 results.
The company's worse-than-expected Q2 results have led to a drop in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Sleep Number shares tumbled 28.8% after mixed Q2 results.
The company's mixed Q2 results have led to a significant drop in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Sanofi shares fell 3.1% after Q2 results and raised earnings forecast.
Despite positive Q2 results and a raised earnings forecast, the company's stock price has fallen.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
UroGen Pharma shares fell 8.7% despite positive topline data from its Phase 3 trials.
Despite positive Phase 3 trials data, the company's stock price has fallen.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100